The recent Annual Meeting of ESHO (European Society for Hyperthermic Oncology), November 6-8, 2024, showcased significant developments in hyperthermic oncology, with particular emphasis on combined treatment protocols and technical and clinical quality assurance.
The topics with particular relevance for the field of wIRA superficial and whole-body hyperthermia were:
Combined Hyperthermia-Immunotherapy: Novel basic research findings on synergistic effects were presented (e.g., OP-01), alongside clinical implementations, including a noteworthy case report combining CAPOX, Nivolumab, and fever-range whole-body hyperthermia in gastric cancer treatment (FP-37).
Advances in Superficial Hyperthermia: Dr. Notter (Lindenhofspital Bern) and Dr. Thomsen (University Medical Center Freiburg) presented developments in thermography-controlled wIRA superficial hyperthermia, including updates on the ongoing HISTOTHERM study (OP-19). Additionally, T. Lushchaeva (University Medical Center Magdeburg) introduced a prospective study protocol focusing on primary angiosarcoma (FP-16), and D. Marder from Katonspital Aarau presented the development of a phantom for infrared hyperthermia required for quality assurance (FP-15).
Renewed Interest in Extreme Whole-Body Hyperthermia: Preliminary results from an ongoing study investigating extreme WBH in metastatic pancreatic cancer were presented by J.-P. Bogers, ELMEDIX Belgium, developer of a new technology for extreme WBH.
For detailed information, please refer to ESHO_2024_Abstracts.pdf. Abstracts related to wIRA hyperthermia and fever-range applications are OP-01, OP-19, OP-41, FP-10, FP-15, FP-16, FP-33, FP-37.
Lecture of Dr Markus Notter on Thermography-controlled wIRA superficial hyperthermia
Lecture of Dr Andreas Thomsen on HISTOTHERM study in Freiburg
Fast presentation of medical physisist Dietmar Marder (Kantonsspital Aarau) on a phantom for infrared superficial hyperthermia
Fast presentation of Tatiana Lushchaeva (university Medical Center Magdeburg) on a study design for head&neck angiosarcoma
ESHO president Hans Crezee with a slide of the sponsors
JP Bogers (ELMEDIX, Belgium) presenting the project of a new system for extreme WBH
